IOM: nevirapine study is reliable.
The Institute of Medicine re-analyzed the key study that first showed prevention of mother-to-child HIV transmission by single-dose nevirapine. The IOM released a 150-page report concluding that the study was properly conducted and its results are valid.
James
John S
JS
D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine